These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

83 related articles for article (PubMed ID: 12005110)

  • 61. Escitalopram and QTc prolongation.
    Hasnain M; Howland RH; Vieweg WV
    J Psychiatry Neurosci; 2013 Jul; 38(4):E11. PubMed ID: 23791140
    [No Abstract]   [Full Text] [Related]  

  • 62. Efficacy and safety of escitalopram versus citalopram in major depressive disorder: a 6-week, multicenter, randomized, double-blind, flexible-dose study.
    Ou JJ; Xun GL; Wu RR; Li LH; Fang MS; Zhang HG; Xie SP; Shi JG; Du B; Yuan XQ; Zhao JP
    Psychopharmacology (Berl); 2011 Feb; 213(2-3):639-46. PubMed ID: 20340011
    [TBL] [Abstract][Full Text] [Related]  

  • 63. SSRIs and intraocular pressure modifications: evidence, therapeutic implications and possible mechanisms.
    Costagliola C; Parmeggiani F; Sebastiani A
    CNS Drugs; 2004; 18(8):475-84. PubMed ID: 15182218
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Escitalopram (S-enantiomer of citalopram): clinical efficacy and onset of action predicted from a rat model.
    Montgomery SA; Loft H; Sánchez C; Reines EH; Papp M
    Pharmacol Toxicol; 2001 May; 88(5):282-6. PubMed ID: 11393591
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Efficacy of escitalopram in patients with severe depression: a pooled analysis.
    Llorca PM; Azorin JM; Despiegel N; Verpillat P
    Int J Clin Pract; 2005 Mar; 59(3):268-75. PubMed ID: 15857321
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Introduction. Overview of citalopram.
    Lippa AS; Beer B; Cancro R
    J Clin Psychopharmacol; 1999 Oct; 19(5 Suppl 1):1S-3S. PubMed ID: 10507504
    [No Abstract]   [Full Text] [Related]  

  • 67. The preclinical observation that escitalopram possesses a faster time to onset of efficacy than citalopram.
    Håkanson R
    Pharmacol Toxicol; 2002 Jan; 90(1):3-4. PubMed ID: 12005110
    [No Abstract]   [Full Text] [Related]  

  • 68. Escitalopram: efficacy and tolerability in the treatment of depression.
    Baldwin DS
    Hosp Med; 2002 Nov; 63(11):668-71. PubMed ID: 12474611
    [TBL] [Abstract][Full Text] [Related]  

  • 69. [Escitalopram: a chiral agent for treatment of depression].
    Overlack M; Davids E; Gastpar M
    Med Monatsschr Pharm; 2004 May; 27(5):148-51. PubMed ID: 15171592
    [No Abstract]   [Full Text] [Related]  

  • 70. Clinical development of citalopram.
    Willetts J; Lippa A; Beer B
    J Clin Psychopharmacol; 1999 Oct; 19(5 Suppl 1):36S-46S. PubMed ID: 10507507
    [No Abstract]   [Full Text] [Related]  

  • 71. Escitalopram: a pharmacoeconomic review of its use in depression.
    Croom KF; Plosker GL
    Pharmacoeconomics; 2003; 21(16):1185-209. PubMed ID: 14594439
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Is the significant superiority of escitalopram compared with other antidepressants clinically relevant?
    Montgomery SA; Möller HJ
    Int Clin Psychopharmacol; 2009 May; 24(3):111-8. PubMed ID: 19357527
    [TBL] [Abstract][Full Text] [Related]  

  • 73. [Severe forms of depression: the efficacy of escitalopram].
    Spadone C
    Encephale; 2009 Apr; 35(2):152-9. PubMed ID: 19393384
    [TBL] [Abstract][Full Text] [Related]  

  • 74.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 75.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 76.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 77.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 78.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 79.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 80.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.